Physician profile
Thomas Chu
NPI 1972825222
$8,648.45
in general payments reported to CMS, 2019-2025
30 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,562 · 2022: $1,472 · 2023: $1,522 · 2024: $2,034 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,472 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,472.39 |
| Education | $141.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,737.62 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Csl Behring | $897.66 | 2021-2024 | Haegarda |
| Amgen INC. | $825.84 | 2021-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $626.53 | 2021-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $626.37 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $511.35 | 2021-2025 | Takhzyro, Hyqvia |
| Novartis Pharmaceuticals Corporation | $440.96 | 2021-2025 | |
| Leo Pharma INC. | $431.41 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $308.51 | 2024-2025 | |
| Pfizer INC. | $231.91 | 2021-2023 | |
| Genentech USA, INC. | $138.51 | 2021-2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $130.61 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Scynexis, INC. | $88.57 | 2022 | |
| Horizon Therapeutics Plc | $81.80 | 2022-2023 | Actimmune |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $76.27 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $61.23 | 2021 | |
| Abbvie INC. | $45.12 | 2021-2022 | |
| Mylan Specialty L.P. | $43.11 | 2021-2023 | Yupelri |
| Octapharma USA, INC. | $30.94 | 2021 | |
| Organon LLC | $29.74 | 2025 | Vtama |
| Covis Pharma Gmbh | $28.46 | 2021 | |
| La Jolla Pharmaceutical Company | $27.47 | 2023 | Giapreza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.02 | 2021 | |
| Galderma Laboratories, L.P. | $20.77 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $20.20 | 2023 | Ryaltris |
| Dermavant Sciences, INC. | $19.58 | 2024 | Vtama |
| Viatris Specialty LLC | $17.59 | 2025 | Yupelri |
| Optinose US, INC. | $15.48 | 2021 | |
| Pharming Healthcare, INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.